Mark McCleland

Mark McCleland has a diverse work experience in the pharmaceutical and healthcare industry. Mark currently works at Amunix Pharmaceuticals as the Global Project Head and Head of Clinical Translational Development since July 2022. Prior to this, they worked at Erasca, Inc. as the Senior Director and Head of Clinical Biomarker and CDx Development from April 2021 to July 2022. Mark has also held several roles at Genentech, including Senior/Principal Scientific Manager, Oncology Biomarker Development from June 2019 to April 2021, Senior Companion Diagnostics Project Leader from July 2018 to July 2019, Companion Diagnostics Project Leader from March 2016 to July 2018, and Senior Scientific Researcher from February 2010 to February 2016.

Before joining Genentech, they gained valuable research experience at the University of California, San Francisco as a Post-Doctoral Fellow from January 2005 to February 2010. During their time at UCSF, they conducted research on cell cycle changes during developmental progression in Drosophila and published multiple papers. Mark also completed a summer internship at DuPont Pharmaceuticals in 1999 and a summer internship in Gene Therapy at The Children's Hospital of Philadelphia in 1998.

Mark McCleland earned their Bachelor of Science degree in Biochemistry, Summa cum laude, from Lycoming College. Mark attended Lycoming College from 1995 to 1999. Following their undergraduate studies, Mark pursued further education at the University of Virginia, where they obtained their Ph.D. in Biochemistry and Molecular Genetics. Mark completed their doctoral studies from 1999 to 2004.